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Abstract
TheRaf/MEK/ERKpathway is an importantmediator of tumor cell proliferation and angiogenesis.Here,we investigated
the growth-inhibitory and antiangiogenic properties of PD0325901, a novel MEK inhibitor, in human melanoma cells.
PD0325901 effects were determined in a panel of melanoma cell lines with different genetic aberrations. PD0325901
markedly inhibited ERK phosphorylation and growth of both BRAFmutant and wild-typemelanoma cell lines, with IC50
in the nanomolar range even in the least responsive models. Growth inhibition was observed both in vitro and in vivo
in xenograft models, regardless of BRAF mutation status, and was due to G1-phase cell cycle arrest and subsequent
induction of apoptosis. Cell cycle (cyclin D1, c-Myc, and p27KIP1) and apoptosis (Bcl-2 and survivin) regulators were
modulated by PD0325901 at the protein level. Gene expression profiling revealed profound modulation of several
genes involved in the negative control of MAPK signaling and melanoma cell differentiation, suggesting alternative,
potentially relevant mechanisms of action. Finally, PD0325901 inhibited the production of the proangiogenic factors
vascular endothelial growth factor and interleukin 8 at a transcriptional level. In conclusion, PD0325901 exerts potent
growth-inhibitory, proapoptotic, and antiangiogenic activity in melanoma lines, regardless of their BRAF mutation
status. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more
effective treatment strategies for patients experiencing malignant melanoma.
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Introduction
The mitogen-activated protein kinase (MAPK) signal transduc-
tion pathway controls key cellular processes such as proliferation,
differentiation, and survival. Among four major MAPK modules,
the one converging on the activation of extracellular signal–regulated
kinase (ERK) and its upstream activator MAPK and ERK kinase
(MEK) is the most extensively studied and perhaps the most rele-
vant to cancer pathogenesis and therapy [1,2]. Although onco-
genic mutations of either MEK or ERK have not been identified
in human tumors, their constitutive activation is sufficient to trans-
form mammalian cells; moreover, the MEK/ERK kinase module
serves as a focal point in the signal transduction pathway of known
oncogenes, such as RAS or RAF [3] and disruption of its activity
by pharmacological inhibitors severely impairs the transforming
ability of many upstream-acting cellular oncogenes [4,5]. As a result,
aberrant activation of the MEK/ERK pathway is observed in a large
proportion of human cancers, including a wide variety of solid tu-
mors and hematological malignancies, and has recently emerged
as a promising target for anticancer therapies [2,6,7]. In addition
to its role in fostering cancer cells’ proliferation and survival, the
MAPK module converging on ERK activation is also an important
regulator of angiogenesis: indeed, MAPK activity controls vascular
endothelial growth factor (VEGF) expression, through both hypoxia-
inducible factor 1 (HIF-1)–dependent and Sp1/AP-2–dependentmech-
anisms [8].
Constitutive ERK activation is observed in virtually all melanomas
[9,10], where MAPK is activated by the production of autocrine
growth factors or, more rarely, by mutational activation of growth factor
receptors, such as c-kit.Most commonly, however, ERK is constitutively
activated as a result of gain-of-function mutations in pathway elements
that are immediately upstream of MEK, either NRAS or BRAF [11–
13]. The latter is arguably the most common mutational event in
human melanoma, where it is observed in up to 70% of cases; BRAF
mutations result in the aberrant activation of ERK, which, in turn, pro-
vides an essential tumor growth and maintenance signal by fostering
proliferation, survival, chemoresistance, and the autocrine production
of proangiogenic factors, such as VEGF [10,14]. Most interestingly
from a therapeutic perspective, BRAF mutations may constitute the
Achilles’ heel of malignant melanoma because BRAF-mutated tumors
seem to be exquisitely sensitive to clinically available MEK inhibitors
[15]. From amolecular standpoint, data fromGarnett et al. [16] indicate
that, although a small fraction of BRAFmutations generates an enzyme
that is impaired in its ability to activate the downstream MEK/ERK
cascade, kinase-impaired mutants also work through the mitogenic
cascade culminating in ERK activation. The mechanism is a rescue of
kinase-impaired mutant BRAF by wild-type CRAF through a process
that involves 14-3-3–mediated hetero-oligomerization and transactiva-
tion [16,17].
Here, we investigated the therapeutic potential of the novel, potent,
and selective MEK inhibitor, PD0325901, against melanoma cells.
PD0325901 is a noncompetitive MEK inhibitor, with improved oral
bioavailability and aqueous solubility, compared with its parent com-
pound CI-1040, and is currently in phase 1/2 clinical development
in different solid tumors, including malignant melanoma [1,2,18]. In
preclinical models of human melanoma, we found that PD0325901
potently inhibits cell growth, promotes apoptosis, and decreases the
production of proangiogenic factors, such as VEGF and interleukin
8 (CXCL8).
Materials and Methods
Melanoma Cell Lines and In Vitro Treatments
ME1007, ME4405, ME4686, ME8959, ME10538, and ME13923
human melanoma cell lines were established at the Istituto Nazionale
Tumori (Milan, Italy), as previously described [19]; the JR8 melanoma
cell line was established at the Regina Elena Cancer Institute [20]; all
other cell lines were purchased from American Type Culture Collection
(ATCC, Manassas, VA). Cell lines were maintained in RPMI 1640
medium (Invitrogen, Milan, Italy) containing 10% of FBS, 2 mM L-
glutamine, and antibiotics at 37°Cunder 5%CO2–95%air. PD0325901
[N -((R)-2,3-dihydroxy-propoxy)-3,4-diXuoro-2-(2-Xuoro-4-iodo-
phenylamino)-benzamide] was obtained from Pfizer Global Research
and Development (Ann Arbor, MI). The drug was dissolved in DMSO
as a 10-mM stock solution, stored at −20°C, and adjusted to the final
concentration with culture medium.
For IC50 assays, exponentially growing cells were exposed to in-
creasing concentrations of PD0325901 (0.1-1000 nM) for 24, 48, or
72 hours. Cells were then assayed for cell viability (by trypan blue exclu-
sion test) and counted using a Coulter Counter (Kontron Instruments,
Milan, Italy). The IC50 value was calculated according to the Chou-
Talalay method using the Calcusyn software.
Clonogenic Assay
To evaluate colony-forming ability, melanoma cells were seeded in
60-mm Petri dishes at a density of 500 cells per dish and cultured
in medium with or without PD0325901. After 7 days of incubation,
colonies were fixed with methanol, stained with 2% methylene blue
in 95% ethanol/5% water (v/v), and counted under a light microscope
(1 colony ≥ 50 cells). All experiments were performed in triplicate.
In Vivo Xenografts
Female CD-1 nude (nu/nu) mice, 6 to 8 weeks old, were used
(Charles River Laboratories, Calco, Italy). Mice were housed under
pathogen-free conditions, and all procedures involving animals and
their care were in agreement with national and international laws
and policies. Solid tumors were obtained by subcutaneous injection
of 1.5 or 2 × 106 viable cells for M14 (BRAFV600E) and ME8959
(wtBRAF ), respectively. Each experimental group included 8 to 10
animals. PD0325901 was formulated in 0.5% hydroxypropyl methyl-
cellulose plus 0.2% Tween 80 and administered by oral gavage at the
dosage of 50 mg/kg per day; treatment was started when the tumor
mass reached 100 mg. Untreated mice and mice treated with an equal
amount of vehicle were used as control groups. The drug was admin-
istered daily for 21 days, and tumor size was measured every 2 to 3 days.
Mice were killed when tumor volume reached more than 2000mg, and
tumors were excised and placed in 10% buffered formaldehyde. Tumor
weight was calculated from caliper measurements according to the fol-
lowing formula: tumor weight (mg) = length (mm) × width (mm)2 / 2.
Western Blot Analysis
ForWestern blot analysis, 35μg of total protein, prepared as described
previously [21], was fractionated by SDS–polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membrane (Amersham,
Chicago, IL). Membranes were probed with primary antibody (Ab),
and the signal was detected using peroxidase-conjugated antimouse or
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antirabbit secondary Abs (Cell Signaling Technology, Inc, Beverly,
MA). The following primary Abs were used: anti–HIF-1α or anti–
HIF-1β/ARNT1 (BD Biosciences, San Jose, CA); Abs specific for
phosphorylated (Thr202/Tyr204) and total ERK-1/2 (Cell Signaling
Technology, Inc); anti–myeloid cell leukemia-1 (BD Biosciences);
anti–B-cell lymphoma-2 (Dako, Carpinteria, CA); antisurvivin (R&D
System, Minneapolis, MN); and anti-p27Kip1 and anti–c-Myc (Santa
Cruz Biotechnology, Santa Cruz, CA). To check the amount of proteins
transferred to the nitrocellulose membrane, β-actin was used and de-
tected by anti–β-actin (clone AC-15; Sigma, St. Louis, MO).
Cell Cycle and Apoptosis Analysis
Cells were fixed in ice-cold ethanol (70% vol/vol) and stained with
propidium iodide (PI; 25 mg/ml PI, 180 U/ml RNase, 0.1% Triton
X-100, and 30 mg/ml polyethylene glycol in 4 mM citrate buffer,
pH 7.8; Sigma). The DNA content was determined using a FACScan
flow cytometer (Becton Dickinson, San Jose, CA). Cell cycle distribu-
tion was analyzed using the ModFit LT software (Verity Software
House, Topsham, ME). For annexin V binding studies, the cells were
stained with fluorescein isothiocyanate–conjugated annexin Vusing the
Vybrant Apoptosis Kit (Molecular Probes, Eugene, OR) and analyzed
by flow cytometry while simultaneously assessing membrane integrity
by PI exclusion.
Microarray Analysis
Total RNA was extracted using the Trizol reagent (Invitrogen,
Carlsbad, CA), followed by additional purification with the RNeasy
kit from Qiagen (Valencia, CA). Five micrograms of each RNA sample
was retrotranscribed to double-stranded complementary DNA (cDNA)
and labeled through in vitro transcription by the One-cycle cDNA
synthesis/GeneChip IVT labeling kit (Affymetrix, Santa Clara, CA).
Twenty micrograms of biotin-labeled complementary RNA was frag-
mented and hybridized to the Human Genome U133 Plus 2.0 Gene-
Chip array (Affymetrix) overnight at 45°C using a Hybridization Oven
640 (Affymetrix). The hybridized probe arrays were washed and stained
with the streptavidin-phycoerythrin conjugate (Molecular Probes,
Invitrogen) using the Fluidic Station 450 (Affymetrix) and were scanned
by the GeneChip Scanner 3000 (Affymetrix).
For statistical analysis, Affymetrix gene expression data were pro-
cessed with the dChip software (www.dchip.org), which uses an invari-
ant set normalization method. The array with the median overall
intensity was chosen as the baseline for normalization. Model-based
expressions were computed for each array and probe set, using only
perfect match probes. For unsupervised analysis, the following non-
specific filtering criteria were used: 1) gene expression level was required
to be higher than 100 in at least 30% of the samples and 2) the ratio of
the SD to the mean expression across all samples was required to be
between 0.5 and 10. Supervised analyses were performed to compare
DMSO-treated cells with PD0325901-treated cells at 6 and 24 hours.
For these comparisons, a t test was used: only the genes with expression
higher than 100, P ≤ .05, and a fold change of 2 or higher were retained.
Hypoxia and ELISA Assay
The cells were cultured in serum-free medium in a humidified atmo-
sphere with 95% air and 5% CO2 (normoxia) or were incubated in
specially designed aluminum chambers flushed with a gas mixture con-
taining 5% CO2 and 95% N2 [21]. VEGF analyses–ELISA Kit and
CXCL8 analysis–ELISA Kit (R&D Systems, Minneapolis, MN) were
used to determine the amount of either VEGF or CXCL8 protein levels
in the conditioned medium. The sensitivity of the VEGF and CXCL8
assays was 31.2 pg/ml.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay (EMSA) was performed after
exposure to either normoxic or hypoxic conditions for 24 hours in
the presence or absence of PD0325901, as previously described [22].
The following double-strand oligomers were used as labeled probes or
cold competitors: HIF-1 (human VEGF 5′ gene promoter), 5′TCGA-
CCACAGT-GCATACGTGGGCTCCAACAGGTCCTCTTC-3′
[21,23]; activator protein-1 (AP-1; human CXCL8 5′ gene promoter),
GTG TGATGACTC AGG TTTG [24]. Oligonucleotides were pur-
chased from Invitrogen. In competition assays, a 100× unlabeled com-
petitor was added at the same time of probe addition. In supershift
analyses, 2 μl (2 mg/ml) of anti–c-jun, anti–B-jun, or anti–c-fos Abs
(Santa Cruz Biotechnology) were added to the reaction.
Human Angiogenesis Antibody Arrays
The Human Angiogenesis Antibody Array I (RayBiotech, Inc,
Norcross, GA) was used according to the manufacturer’s protocol in
evaluating the secretion of 20 angiogenic factors into the conditioned
medium of the different lines. Membranes spotted in duplicate with
Abs against angiogenic factors were incubated overnight with the
conditioned medium. The signals on the membranes were detected
by chemiluminescence. The intensity of protein signal (two spots for
each protein) was compared with the relative positive signals by densi-
tometric analysis.
Results
PD0325901 Inhibits Constitutive ERK Phosphorylation
in Human Melanoma
First, we evaluated the effect of PD0325901 on ERK phosphoryla-
tion in M14 and other human melanoma cell lines. PD0325901 dose-
dependently inhibited the phosphorylation of ERK and its downstream
target ribosomal S6 kinase (p90RSK1), without affecting total levels of
ERK protein expression, in the M14 model (Figure 1A). Similar results
were obtained in the othermelanoma cell lines tested (FigureW1A; data
not shown), regardless of their BRAF mutation status. Inhibition of
ERK phosphorylation after exposure to PD0325901 was rapid (com-
plete inhibition observed within 15 minutes) and persisted for at least
72 hours (Figure 1B).
These results indicate that PD0325901 is a potent inhibitor of
MEK-to-ERK signaling in human melanoma cells.
PD0325901 Inhibits the Growth of Human Melanoma
Cell Lines In Vitro
The growth-inhibitory properties of PD0325901were assessed in vitro
on a panel of 11 human melanoma cell lines previously characterized
for the presence or absence of BRAF, NRAS, and TP53mutations and
for PTEN expression [19].
As shown in Table 1, PD0325901 potently (IC50, 20-50 nM) inhib-
ited the growth of human melanoma cell lines with (M14, A375P,
M, and SM, ME10538, ME4686, JR8) or without (ME4405 and
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ME13923) BRAF mutations. ME1007 and ME8959, both of which
had wild-type BRAF, were slightly more resistant to PD0325901-
mediated growth inhibition (IC50, ≥100 nM).
As exemplified in Figure 2A for the BRAFV600E cell line M14,
PD0325901-induced growth inhibition was dose- and time-dependent.
Although the potency of PD0325901 in inhibiting ERK phosphoryla-
tion was essentially unchanged, its growth-inhibitory activity was strik-
ingly potentiated under low serum (2% fetal calf serum) conditions,
resulting in an IC50 of less than 1 nM in the M14 model. We further
characterized the effect of PD0325901 using a clonogenic growth assay.
M14 cells were seeded at cloning densities (500 cells/cm2) in serum
medium and cultured for 7 days in the presence or absence of increasing
PD0325901 concentrations (0.1-1000 nM); as shown in Figure 2, B
and C , PD0325901 strikingly reduced M14 clonogenic growth, with
50% inhibition observed at approximately 0.1 nM.
PD0325901 Inhibits the Growth of Human Melanoma
Cell Lines In Vivo
To further evaluate PD0325901-induced melanoma growth in-
hibition, we tested the drug in vivo in xenograft models obtained
by subcutaneous injection of either M14 (BRAFV600E) or ME8959
(wtBRAF ). Preliminary experiments conducted with M14-derived tu-
mors indicated that in vivo growth inhibition was dosage-dependent,
with 50 mg/kg per day being significantly more effective than
25 mg/kg per day, without gross signs of toxicity (Figure W2A); we
therefore used the 50 mg/kg per day for further experiments. As shown
in Figure 3A, daily oral treatment of established tumors with 50 mg/kg
per day of PD0325901 significantly impaired in vivo tumor growth
(60%-65% inhibition compared with controls at the end of a 21-day
treatment cycle) in both M14 and ME8959 xenografts. The effects
of PD0325901 were reversible, and tumors grew back after treatment
interruption (data not shown). Upon microscopic examination of
M14-derived tumors, PD0325901-treated tumors lost the characteris-
tic nodular architecture, showing almost no stroma or blood vessel
formation either at the periphery or within the tumor mass; displayed
larger areas of necrosis, with only cells immediately adjacent to blood
vessels surviving; and seemed more differentiated with a reduction
in the number of aberrant mitosis and striking normalization of the
characteristic nuclear and chromatin pleomorphism (Figure 3B). Simi-
lar results were obtained in the ME8959 tumor model (data not
shown). In particular, by the end of the treatment period, microvessel
density was significantly decreased by PD0325901 in both xenograft
models (Figure W2B).
Overall, these results indicate that PD0325901 exerts potent
growth-inhibitory effects in human melanoma cell lines, regardless of
BRAF mutations.
Table 1. PD0325901 IC50 for Cell Growth According to Melanoma Cell Lines’ Mutational Status.
Cell Line PTEN TP53 NRAS BRAF PD0325901 IC50 (nM)
M14 wt/+ wt wt V600E 23 ± 4
A375 P wt/+ wt wt V600E 48 ± 2
A375 M wt/+ wt wt V600E 53 ± 4
A375 SM wt/+ wt wt V600E 56 ± 3
JR8 NA NA NA V600E 44 ± 2
ME4405 wt/+ NA Q61R wt 33 ± 2
ME10538 wt/+ wt wt V600E 27 ± 5
ME1007 wt/+ R213R wt wt 97 ± 9
ME8959 wt/+ wt Q61R wt 209 ± 23
ME4686 P38S S127F/++ wt V600E 32 ± 2
ME13923 wt/+ wt wt wt 38 ± 8
+ indicates protein expressed; ++, p53 protein overexpressed; NA, not assessed; wt, wild-type gene.
Figure 1. PD0325901 inhibits constitutive ERK phosphorylation in human melanoma cells. (A) Dose-response: M14 cells were exposed
to PD0325901 at the indicated concentrations for 24 hours, lysed, and subjected to Western blot analysis using Abs specific for doubly
phosphorylated ERK-1/2 (p-ERK), total ERK-1/2 (ERK), and phosphorylated p90RSK (p-p90RSK). Western blot with Abs specific for β-actin is
shown as protein loading and blotting control. Results from one experiment representative of at least three independent experiments
performed with superimposable results are shown. (B) Time course: M14 cells were exposed to 10 nM PD0325901 or a matched con-
centration of vehicle for the indicated periods; protein lysates were then analyzed by Western blot using Abs directed against phos-
phorylated (p-ERK) or total ERK (ERK). Western blot with Abs specific for β-actin is shown as protein loading and blotting control. Results
from one experiment representative of at least three independent experiments performed with superimposable results are shown.
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MEK Blockade Inhibits Cell Cycle Progression and Induces
Apoptosis in Human Melanoma Cell Lines
Using the BRAFV600E cell line M14 as a model, we analyzed the
mechanisms of PD0325901-induced growth inhibition in further de-
tail. Exposure of M14 cells to PD0325901 caused a dose- and time-
dependent cell cycle accumulation at the G1/S boundary and depletion
of cells in the S-phase (Figure 4, A and B). Moreover, exposure of M14
cells to PD0325901 caused a dose- and time-dependent increase in the
percentage of cells with sub-G1DNAcontent, thus indicating induction
of apoptosis (Figure 4C). Comparedwith the kinetics and dose-response
curve of cell cycle inhibition, DNA decrease to sub-G1 levels required
longer times of exposure (72 hours) and higher concentrations of the
drug (≥100 nM). The apoptotic nature of PD0325901-induced cell
death was further confirmed by annexin V binding, which displayed a
Figure 2. PD0325901 inhibits the growth of human melanoma cell lines in vitro. (A) Growth curves: M14 cells were exposed to increasing
concentrations of PD0325901 for the indicated periods and then assessed for cell viability by trypan blue exclusion counting. Results are
expressed as percentage of cells plated at the beginning of the experiment (time 0) and represent the average ± SD of four independent
experiments (*P < .02 by 2-tailed Student’s t test for the comparison between PD0325901- and vehicle control–treated cells at the 72-hour
time point). (B and C) Clonogenic growth: M14 cells were seeded at cloning densities (500 cells per dish) in serummedium and cultured for
7 days in the presence of the indicated PD0325901 concentrations or a matched concentration of vehicle (Control); methylene blue–stained
colonies containing more than 50 cells per colony were then counted under a light microscope. Results from one experiment representa-
tive of at least three performed are shown in panel B. In panel C, results are expressed as percentage of colonies in PD0325901-treated
samples relative to vehicle control–treated samples and represent the average± SDof three independent experiments (*P< .001 by 2-tailed
Student’s t test).
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dose-dependency similar to that observed for the appearance of a hypo-
diploid peak, but was detectable within 48 hours (Figure 4, C and D).
Low serum conditions (2%) significantly potentiated and accelerated
PD0325901-induced apoptosis.
PD0325901 Modulates the Expression of Cell Cycle– and
Apoptosis-Regulating Proteins
We next analyzed the effect of PD0325901 on the expression of
key regulators of cell cycle progression and apoptosis by immunoblot
analysis (Figure 5). Consistent with the observed G1 accumulation, the
protein expression of cyclinD1was strikingly decreased in PD0325901-
treated M14 cells; conversely, the cyclin-dependent kinase inhibitor
p27KIP1 accumulated in PD0325901-treated cells in a dose- and time-
dependent fashion. PD0325901 also substantially, although not com-
pletely, inhibited c-myc expression. Relatively high concentrations of
PD0325901 (100 nM) strikingly downregulated Bcl-2 protein expres-
sion, leaving the expression of Bcl-xL and Mcl-1 unaffected. Survivin
was also strikingly downregulated by PD0325901 treatment (Figure 5).
Gene Expression Profiling
To gain further insights into the molecular mechanisms of action
of PD0325901, changes in the gene expression profiles were analyzed
Figure 3. PD0325901 inhibits the growth of human melanoma cell lines in vivo. (A) In vivo growth curves: In vivo passaged M14 and
ME8959 cells (1.5 and 2.0 × 106 cells, respectively) were injected subcutaneously in the flank region of nude mice and allowed to form
established tumors. When tumors became palpable (days 11 and 9 for M14 and ME8959, respectively), mice were randomly assigned to
one of the following treatment groups (10 mice per group): no treatment (Control), vehicle only (Vehicle), or PD0325901 50 mg/kg per
day by oral gavage for 21 consecutive days. Tumor size was measured by caliper every 2 to 3 days. Arrows indicate treatment start and
stop. Results from one experiment representative of at least two performed are shown and are expressed as average tumor weight
(mg) ± SD for each treatment group (*P< .05 by 2-tailed Student’s t test for the comparison between PD0325901-treated and combined
untreated and vehicle control–treated cells). (B) Microphotographs of hematoxylin/eosin staining of paraffin-embedded tumors from
vehicle control– and PD0325901-treated animals killed at day 31 after injection of M14 cells (original magnifications, ×2.5, ×10, and
×20). Results from one experiment representative of at least two performed are shown. Similar results were obtained when animals
were killed at day 27 or 38 after injection.
Neoplasia Vol. 11, No. 8, 2009 Therapeutic Potential of PD0325901 in Melanoma Ciuffreda et al. 725
in M14 cells exposed to the drug for 6 and 24 hours. Supervised
comparison between treated and untreated samples after 6 hours
highlighted a large set of modulated genes (n = 557), 57 of which
remained concordantly modulated at the 24-hour time point (Fig-
ure 6). Among 163 gene ontology-annotated genes upregulated by
PD0325901 treatment, transporters (particularly members of the
solute carrier family of proteins) and transcription modulators were
clearly overrepresented (19 and 17 probe sets, respectively; Figure 6B).
Interestingly, several genes related to melanocyte differentiation and
melanin biosynthetic pathway were upregulated by PD0325901, as
were semaphorin 6A (6- to 13-fold up-regulation with four different
probe sets) and cyclin G2 (4.7-fold; TableW1).Transcriptionmodulators
and transporters were also the most represented among the 225 genes
downregulated by PD0325901 (34 and 20 genes, respectively; Fig-
ure 6B), immediately followed by cell cycle/cell division (20 genes),
translation (11 genes), and apoptosis (8 genes) regulators. Interestingly,
genes involved in the control of signal transduction and MAPK activ-
ity, such asDUSP-4 and -6 and SPRY-2 and -4, were among those most
profoundly downmodulated by PD0325901 (29- to 95-fold forDUSP-6;
TableW1). Cell cycle and apoptosis regulators whose protein expression
was decreased by PD0325901 treatment, such as cyclin D1 and c-myc,
were also found to be significantly downregulated at the messenger
RNA (mRNA) level (seven- to nine-fold and six-fold, respectively). Fi-
nally, several angiogenesis-/tissue remodeling–related genes, including
VEGF-A and CXCL8, were modulated on PD0325901 treatment.
PD0325901 Inhibits VEGF Production
We next examined the effects of PD0325901 on the production
of VEGF. Exposure of M14 cells to increasing concentrations of
PD0325901 (1-100 nM) for 24 hours resulted in a significant (P ≤
.01 for PD0325901 concentrations ≥10 nM) and dose-dependent
inhibition of VEGF release in culture-conditioned medium, as mea-
sured by ELISA, under both normoxic and hypoxic conditions (Fig-
ure 7A). Similar results were obtained in other melanoma cell lines
that did not harbor BRAF mutations (ME13923 and ME8959
Figure 4.MEK blockade inhibits cell cycle progression and induces apoptosis in human melanoma cell lines. M14 cells were exposed to
increasing concentrations of PD0325901 for the indicated periods and then assessed for cell cycle distribution and apoptosis. (A and B)
Cell cycle analysis: Distribution of PD0325901- and control vehicle–treated cells in the different phases of cell cycle was assessed by PI
DNA staining; results from one experiment representative of at least three performed are shown in panel A. In panel B, results are
expressed as percentage of cells in the S phase of the cell cycle and represent the average ± SD of three independent experiments
(*P ≤ .03 by 2-tailed Student’s t test for the comparison between PD0325901- and vehicle control–treated cells). (C and D) Apoptosis
analysis: Apoptosis induction was assessed by evaluating the percentage of cells with sub-G1 DNA content (PI staining) and by annexin
V/PI staining after exposure to PD0325901; results from one experiment representative of at least three performed are shown in panel C.
In panel D, results are expressed as a percentage of apoptotic cells and represent the average ± SD of three independent experiments
(*P ≤ .02 by 2-tailed Student’s t test for the comparison between PD0325901- and vehicle control–treated cells).
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[Figure W1B; data not shown]; ME1007 had barely detectable VEGF
levels even after hypoxic stimulation and were therefore not evaluable
for the effect of PD0325901 on VEGF production [data not shown]).
PD0325901-mediated down-regulation of VEGF production took
place, at least in part, at the transcriptional level, as indicated by a
2.7-fold decrease in VEGF mRNA detected by gene expression pro-
filing. We next analyzed whether PD0325901 affected the expression
and function of the transcriptional complex HIF-1. As expected [25],
expression of the HIF-1α subunit was undetectable under normoxic
conditions and was strongly induced by exposure to hypoxia in M14
cells (Figure 7B); under hypoxic conditions, exposure to PD0325901
for 24 hours strikingly reduced HIF-1α protein levels. In contrast, the
levels of the HIF-1β subunit were unaffected by MEK inhibition.
Moreover, PD0325901 dose-dependently decreased HIF-1 binding
to the putative hypoxia-responsive element in the VEGF promoter un-
der hypoxic conditions, as evaluated by EMSA (Figure 7C).
Overall, these results indicate that MEK inhibition by PD0325901
inhibits VEGF production by melanoma cells through inhibition of
HIF-1α expression and binding.
PD0325901 Inhibits CXCL8 Production
In addition to VEGF, we screened the expression of other angio-
genic factors in culture-conditioned medium from M14 cells exposed
to PD0325901 using an angiogenesis-oriented Ab array. As shown in
Figure 8A, treatment with PD0325901 under normoxic conditions
strikingly reduced the expression levels of the proangiogenic cytokine
CXCL8. Using ELISA, we confirmed that PD0325901 significantly
(P ≤ .03) and dose-dependently inhibited CXCL8 production (Fig-
ure 8B). Similar results were obtained in other melanoma cell lines
that did not harbor BRAF mutations (ME13923, ME8959, and
ME1007; Figure W1C ; data not shown). PD0325901-mediated
down-regulation of CXCL8 production took place, at least in part,
at the transcriptional level, as indicated by an approximately three-fold
decrease in CXCL8 mRNA detected by gene expression profiling at
24 hours. We next investigated whether PD0325901-mediated down-
regulation of CXCL8 production might involve the AP-1 transcription
factor. As demonstrated by EMSA and supershift assay, PD0325901
dose-dependently decreased the binding to the CXCL8 promoter of
an AP-1 complex containing c-Jun, b-Jun, and c-Fos (Figure 8C).
Overall, these results indicate that MEK inhibition by PD0325901
potently inhibits CXCL8 production by melanoma cells through inhi-
bition of AP-1 binding and transcriptional activity.
Discussion
The MEK/ERK signaling module has recently emerged as a promis-
ing therapeutic target in malignant melanoma [1,2,9,10,26]. Here,
we demonstrate that the novel MEK inhibitor PD0325901 inhibits
in vitro and in vivo growth of human melanoma cell lines, by inhibiting
cell cycle progression and inducing apoptosis, and decreases the produc-
tion of proangiogenic cytokines, such as VEGF and CXCL8.
Sensitivity to MEK blockade–induced growth inhibition has re-
cently been linked to the presence of BRAFmutations [15,27]. Within
the panel of melanoma cell lines we examined, no clear relation-
ship emerges between BRAF mutational status and sensitivity to
PD0325901; although the wtBRAF cell lines ME1007 and ME8959
display a slightly decreased sensitivity to PD0325901-mediated growth
inhibition (Table 1), the sensitivity of other wtBRAF melanoma cell
lines (ME4405 and ME13923) is similar to that of cell lines harbor-
ing the classic BRAFV600E mutation (P = .28, for the comparison
between wt andmutatedBRAF cell lines). In addition, we have evidence
that acute myeloid leukemia cell lines may be extremely sensitive to
PD0325901-mediated growth inhibition, even in the absence of
BRAF mutations (M.R.R., unpublished observations). Most impor-
tantly, in vivo data indicate that PD0325901 treatment induces a similar
degree of growth inhibition in both M14 (harboring the BRAFV600E
mutation) and ME8959 (wtBRAF ) xenograft models (Figure 3A).
Overall, these data leave open the possibility that sensitivity to growth
inhibition by MEK-targeted agents may be sustained by molecular
mechanisms other than BRAF mutations.
Consistent with the prominent role played by theMAPK pathway in
the regulation of G1/S transition [28], the MEK inhibitor PD0325901
exerts predominantly cytostatic effects, inducing G1 cell cycle arrest.
This observation is in line with recently published reports from our
group and others, showing a marked cytostatic effect by first-generation
(CI-1040) or second-generation (PD0325901 and AZD6244) MEK
inhibitors, both in vitro and in vivo [15,27,29–32]. The molecular
mechanisms by which PD0325901 induces G1 arrest in sensitive mela-
noma cells are consistent with current knowledge of ERK actions in cell
cycle progression: the crucial point is inhibition of cyclin D/cyclin–
dependent kinase 4/6 complex activity by FOS/FRA– and MYC-
dependent transcriptional down-regulation of cyclin D1 [33] and
accumulation of the cyclin–dependent kinase inhibitor p27Kip1 [34].
However, high concentrations and prolonged exposure to the drug also
induced apoptosis in a sizable proportion of sensitive melanoma cells,
in agreement with recently published data produced using the U0126
MEK inhibitor [35]. Consistent with the reported role of ERK in coun-
teracting apoptosis at both the mitochondrial and the cytosolic caspase
activation levels [6,7], apoptosis induced by PD0325901 was found to
correlate with down-regulation of Bcl-2 and survivin with very close
Figure 5. PD0325901 modulates the expression of cell cycle– and
apoptosis-regulating proteins. M14 cells were exposed to
PD0325901 (10 and 100 nM) for the indicated periods, then lysed,
and subjected to Western blot analysis using Abs specific for the
indicated cell cycle– and apoptosis-regulating proteins. Western
blot with Abs specific for β-actin is shown as protein loading
and blotting control. Results from one experiment representative
of at least three independent experiments performed with super-
imposable results are shown.
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time- and dose-dependency. These results are consistent with ERK’s
ability to phosphorylate Bcl-2 on Ser52, thereby inhibiting protein
degradation [36], and to increase survivin expression [30,37] and
may be exploited therapeutically to build pharmacological combina-
tions endowed with highly synergistic proapoptotic activity [6,7].
Gene expression profiling experiments indicate that PD0325901
treatment counterregulates many of the genes that have been described
to be differentially expressed in melanoma cells with constitutively ac-
tive ERK [38,39], including CXCL1/GROα, CD73, PLAT, SPRED1,
SPRY2, TFAP2C, TNC, and CXCL8. In addition to genes regulat-
ing cell cycle progression, PD0325901 modulates an array of other
genes involved in molecular circuitries that participate in the regula-
tion of MAPK signaling itself and are potentially relevant for the
anti–melanoma activity of MEK inhibitors [40]. The striking down-
regulation ofDUSP-4 and -6 and SPRY-2 and -4 (TableW1) on exposure
to PD0325901 clearly indicates the interruption of a negative feed-
back loop, by which ERK activation signals the inhibition of signal-
ing through upstream components of the Ras/Raf/MEK/ERK cascade
[41]. Although the functional relevance of disruption of such a negative
feedback in the context of BRAF mutation–driven constitutive ERK
activation in melanoma cells remains to be determined [41,42], it is
interesting to note that similar mechanisms seem to also take place in
PD0325901-sensitive acute myeloid leukemia cells, in which RAF
and MEK hyperphosphorylations are observed in response to MEK
inhibition (M.R.R., unpublished observations). These findings are con-
sistent with the observation of prolonged growth factor–mediated RAF
activation in response to MEK inhibition [43] and support the investi-
gation of vertical combination strategies aimed at inhibiting multiple
signaling elements along the MAPK cascade. Another interesting find-
ing is the marked up-regulation of genes involved in melanoma differ-
entiation and melanin biosynthesis (e.g., TYR, TYRP1, ENDRB) in
response to MEK inhibition by PD0325901 (Figure 6 and Table W1);
in agreement with a recently published report [27], we also observed cell
differentiation and increased melanin production in vivo in M14- and
ME8959-derived xenograft models treated with daily oral PD0325901.
These findings may be of therapeutic relevance in view of recent reports
Figure 6. PD0325901-induced changes in gene expression profiles. M14 cells were exposed to 10 nM PD0325901 or a matched con-
centration of vehicle for 6 and 24 hours, and gene expression profiles were then analyzed using the Affymetrix U133 Plus 2.0 GeneChip
(see also Table W1). (A) Supervised comparison between PD0325901-treated and vehicle control–treated samples reveals a large set of
PD0325901-modulated genes (n = 557) after 6 hours, 57 of which remain concordantly modulated at the 24-hour time point. (B) The
number of genes that were downregulated (white bars, n = 225) or upregulated (gray bars, n= 163) by 6 hours of PD0325901 treatment
in different gene ontology (GO) categories is shown. Results from two independent experiments are shown.
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indicating that MEK inhibition may result in increased melanoma
immune recognition and killing by immune cells through both up-
regulation of differentiation antigens [44] and down-regulation immuno-
suppressive factors [38,45].
Recent data indicate that inhibition of ERK-MAPK signaling in the
tumor vasculature suppresses angiogenesis and tumor growth directly,
by impairing endothelial cell survival and sprouting [46]. Here, we
demonstrate that MEK inhibition by PD0325901 may also interfere
with angiogenesis indirectly by down-regulating the production of pro-
angiogenic factors by tumor cells, in both mutant and wtBRAF cell
line models of melanoma, again arguing against an exclusive role of
BRAF mutational status in determining the outcome upon therapeutic
MEK inhibition. In particular, we focused on the effects of PD0325901
on the production of two major angiogenesis regulators, VEGF-A and
CXCL8. Consistent with previous findings from our group, demon-
strating a pivotal role for ERK activation in Bcl-2 overexpression–driven
VEGF production and angiogenesis in melanoma models [47,48],
PD0325901 significantly decreased VEGF-A production at the mRNA
and protein levels, under both normoxic and hypoxic conditions
(Figure 7A). From a mechanistic standpoint, PD0325901-induced
VEGF down-regulation under hypoxic conditions seems to be related
to the inhibition of HIF-1α protein expression and binding activity at
the VEGF promoter; although the latter is consistent with the proposed
role of ERK in the regulation of HIF-1 transcriptional activity [8,49],
down-regulation of hypoxia-induced HIF-1α protein expression upon
MEK inhibition has not been reported in other tumor models [50].
Whether this observation is related to the cellular model examined or
to the specific MEK inhibitor used (PD0325901) and whether the reg-
ulation of HIF-1α protein expression takes place at the transcription/
translation or protein stability/degradation level remains to be deter-
mined. In addition, PD0325901-induced VEGF down-regulation un-
der normoxic conditions is not clearly related to HIF-1 expression/
transcriptional activity, leaving open the possibility that other ERK-
regulated transcription factors, such as the AP-2/Sp1 complex, may play
a relevant role [51,52]; this hypothesis is supported by gene expression
profiling experiments indicating profound (more than four-fold) down-
regulation of elements of the AP-2 transcriptional complex upon
PD0325901 exposure (Table W1). CXCL8 is an important proinflam-
matory and proangiogenic chemokine involved in melanoma progres-
sion [53], which has been linked to constitutive ERK activation [39].
Our results confirm a prominent role for ERK activation in the regula-
tion of CXCL8 production by melanoma cells at both mRNA and pro-
tein levels and indicate decreased binding of the AP-1 transcriptional
complex to the CXCL8 promoter as a possible molecular mechanism
for PD0325901-induced CXCL8 down-regulation. These findings
are consistent with results demonstrating the modulation of CXCL8
production by AP-1–mediated transcriptional regulation [54]. In addi-
tion to decreased production of proangiogenic cytokines, direct inhibi-
tory effects of PD0325901 on the microenvironment surrounding the
tumor may also play an important role in the inhibition of angiogenesis
observed in vivo (Figure W2B), as suggested by PD0325901-induced
dose-dependent inhibition of endothelial cell and fibroblast prolifera-
tion in vitro (Figure W2C).
Overall, the findings reported herein support the continued develop-
ment of MEK inhibitors, such as PD0325901, as promising therapeu-
tic agents with multiple potentially relevant mechanisms of action
(inhibition of proliferation, induction of apoptosis, inhibition of angio-
genesis) in malignant melanoma; deeper insights into the molecular
mechanisms of action of MEK-targeted agents will likely increase our
Figure 7. PD0325901 inhibits VEGF production. M14 cells were ex-
posed to the indicated concentrations of PD0325901 for 24 hours
under normoxic and hypoxic conditions. (A) VEGF protein expres-
sion was evaluated by ELISA in conditioned medium from M14 cell
cultures. Results are expressed as picograms of VEGF/106 cells/
24 hours and represent the average ± SD of four independent
experiments (*P ≤ .01 by 2-tailed Student’s t test for the com-
parison between PD0325901- and vehicle control–treated cells;
**P = .01 for the comparison between vehicle control–treated cells
under normoxic and hypoxic conditions). (B) Protein samples from
PD0325901- and vehicle control–treated cells were analyzed by
Western blot using Abs against HIF-1α and HIF-1β. Western blot
with Abs specific for heat shock protein 70 (HSP-70) is shown as
protein loading and blotting control. Results from one experiment
representative of at least three performed with superimposable re-
sults are shown. (C) HIF-1 binding to the putative hypoxia responsive
element in the VEGF promoter was evaluated by EMSA. Results
from one experiment representative of at least three performed with
superimposable results are shown.
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chances to successfully translate such exciting preclinical findings into
effective therapies for patients experiencing malignant melanoma.
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Figure W1. PD0325901 effects in the wtBRAFME13923melanoma cell line. (A) Dose-response:ME13923 cells (wtBRAF) were exposed to
PD0325901 at the indicated concentrations for 24 hours, then lysed, and subjected to Western blot analysis using Abs specific for both
phosphorylated ERK-1/2 (p-ERK) and total ERK-1/2 (ERK).Western blot with an Ab specific for β-actin is shown as protein loading and blotting
control. Results from one experiment representative of at least three independent experiments performed with superimposable results are
shown. (B) ME13923 cells were exposed to the indicated concentrations of PD0325901 for 24 hours under normoxic and hypoxic condi-
tions. VEGF protein expression was then evaluated by ELISA in the conditionedmedium fromME13923 cell cultures. Results are expressed
as picograms of VEGF/106 cells/24 hours and represent the average ± SD of four independent experiments (*P ≤ .02 by 2-tailed Student’s
t test for the comparison between PD0325901- and vehicle control–treated cells). (C) CXCL8 protein expression was evaluated by ELISA in
culture-conditioned medium from PD0325901- and vehicle control–treated ME13923 cells. Results are expressed as picograms of CXCL8/
106 cells/24 hours and represent the average ± SD of three independent experiments (*P< .03 by 2-tailed Student’s t test for the compari-
son between PD0325901- and vehicle control–treated cells).
Figure W2. PD0325901 effects on tumor growth andmicrovessel density in vivo and proliferation of normal endothelial cells and fibroblasts
in vitro. (A) In vivo passagedM14 were injected subcutaneously and allowed to form established tumors; mice (10 animals per group) were
then treated with PD0325901 25 or 50 mg/kg per day by oral gavage for 21 consecutive days, starting on day 11 from injection. Tumor size
wasmeasured at the indicated days after injection. Results from one experiment representative of at least two performed are shown and are
expressed as average tumor weight (mg) ± SD for each treatment group; untreated (C) and vehicle-treated (Vehicle) groups were not sig-
nificantly different and were combined for the purpose of this analysis (*P < .0003 by 2-tailed Student’s t test for the comparison between
the 25- and 50-mg/kg per day treatment groups). (B) Blood vessel density was evaluated by histologic examination of M14 (BRAFV600E)-
and ME8959 (wtBRAF)-derived tumors from vehicle control– and PD0325901-treated animals killed 22 and 31 days after injection. At least
10 microscopic fields at an original magnification of ×200 were evaluated for blood vessel density in peripheral areas of tumors without
evidence of necrosis. Results are expressed as the number of blood vessels/5mm2 of tumor area and represent the average ± SD of at least
10 individual sections (*P < .03 and **P = .006 by 2-tailed Student’s t test for the comparison between PD0325901- and vehicle control–
treated tumors). (C) M14 melanoma cells, EA.hy926 immortalized endothelial cells, and NIH3T3 immortalized fibroblasts were exposed to
the indicated concentrations of PD0325901 for 72 hours and then assessed for cell viability by trypan blue exclusion counting. Results are
expressed as the percentage of PD0325901-induced growth inhibition, comparedwith vehicle-treated controls, and represent the average±
SD of at least three independent experiments for each cellular model.
Table W1. Probe Sets Differentially Expressed in M14 Cells After 6 Hours of Treatment with Vehicle or PD0325901.
Probe Sets Gene Symbol P Fold Change* Function
215028_at SEMA6A .017054 13.46 Apoptosis
209348_s_at MAF .017876 12.63 Transcription factor activity
227510_x_at PRO1073 .000874 10.79 Unknown
221310_at FGF14 .001109 10.51 Growth factor activity (MAPK signaling pathway)
206479_at TRPM1 .006097 10.41 Calcium channel activity (inhibition of melanoma metastasis)
221748_s_at TNS1 .011028 9.76 Actin binding
224228_s_at PRDM7 .030223 9.50 DNA binding
240386_at TRPM1 .004726 8.83 Calcium channel activity (inhibition of melanoma metastasis)
225660_at SEMA6A .003206 8.33 Apoptosis
205694_at TYRP1 .002318 7.67 Melanin biosynthetic process from tyrosine
223449_at SEMA6A .00343 7.57 Apoptosis
1553938_a_at STK32A .005098 7.55 Protein serine/threonine kinase activity
206470_at PLXNC1 .02377 7.23 Cell adhesion
209459_s_at ABAT .004474 7.15 Neurotransmitter catabolic process
224823_at MYLK .017689 7.14 Kinase activity
215891_s_at GM2A .001776 7.08 Sphingolipid activator protein activity
203397_s_at GALNT3 .015138 7.05 Transferase activity
232122_s_at VEPH1 .002483 6.94 Unknown
215071_s_at HIST1H2AC .002281 6.79 DNA binding
230795_at Unknown .003112 6.72 Unknown
204273_at EDNRB .000771 6.31 Receptor activity (melanocyte differentiation)
223185_s_at BHLHB3 .005792 6.30 Transcription factor activity
228582_x_at MALAT1 .005132 6.02 Unknown
1569403_at Unknown .005153 5.92 Unknown
220454_s_at SEMA6A .020231 5.92
207069_s_at SMAD6 .00427 5.74 Signal transduction activity
230288_at FGF14 .026675 5.63 Growth factor activity (MAPK signaling pathway)
229334_at RUFY3 .010568 5.44 Unknown
201566_x_at ID2 .046184 5.37 Transcription repressor activity
229866_at Unknown .043934 5.36 Unknown
221618_s_at TAF9B .025783 5.27 Regulation of transcription
214336_s_at COPA .003542 5.27 Protein binding
230741_at Unknown .007443 5.23 Unknown
238376_at KIAA0350 .000807 5.19 Unknown
33646_g_at GM2A .000829 5.19 Sphingolipid activator protein activity
230333_at SAT1 .001292 5.19 Acyltransferase activity
229713_at Unknown .011264 4.95 Unknown
219121_s_at RBM35A .001505 4.88 Unknown
230231_at Unknown .005458 4.83 unknown
201565_s_at ID2 .017147 4.83 Transcription repressor activity
228834_at TOB1 .009895 4.83 Negative regulation of proliferation
225846_at RBM35A .005944 4.79 Unknown
211559_s_at CCNG2 .005645 4.68 Cell cycle checkpoint
209460_at ABAT .006304 4.66 Neurotransmitter catabolic process
227260_at ANKRD10 .007497 4.66 Unknown
202708_s_at HIST2H2BE .008552 4.65 DNA binding
236224_at Unknown .022743 4.61 Unknown
206701_x_at EDNRB .013291 4.56 Receptor activity (melanocyte differentiation)
223795_at TSPAN10 .013945 4.47 Albinism
216512_s_at DCT .01772 4.47 Melanin biosynthetic process from tyrosine
235766_x_at EIF2C2 .007015 4.46 MicroRNA processing
213413_at STON1 .007947 4.43 Endocytosis
244187_at APOOL .010225 4.40 Unknown
227443_at C9orf150 .00613 4.35 Unknown
235060_at KIAA0220-like protein .004534 4.34 Unknown
207323_s_at MBP .001042 4.34 Unknown
205197_s_at ATP7A .003522 4.33 ATP binding
228602_at SGCD .024126 4.33 Cytoskeleton organization
214007_s_at TWF1 .006583 4.32 Actin binding protein
1555419_a_at ASAH1 .033538 4.29 Ceramidase activity
231972_at Unknown .005053 4.26 Unknown
224568_x_at MALAT1 .00334 4.20 Malignant phenotype
239012_at IBRDC2 .006776 4.19 Cell cycle checkpoint p53-dependent
213939_s_at RUFY3 .035913 4.18 Unknown
223824_at C10orf59 .005599 4.15 Monooxygenase activity
244829_at C6orf218 .003371 4.15 Unknown
213139_at SNAI2 .001417 4.13 DNA binding (melanoma metastasis)
213747_at Unknown .006289 4.11 Unknown
202555_s_at MYLK .005803 4.09 Kinase activity
201416_at SOX4 .02817 4.02 Transcription factor
231576_at Unknown .009144 4.00 Unknown
237651_x_at Unknown .002097 3.99 Unknown
205872_x_at PDE4DIP .00451 3.99 Actin binding
209006_s_at C1orf63 .005811 3.94 Unknown
Table W1. (continued )
Probe Sets Gene Symbol P Fold Change* Function
243745_at AP1S2 .012079 3.92 Protein binding
206471_s_at PLXNC1 .006498 3.87 Receptor binding
225237_s_at MSI2 .01728 3.85 RNA binding
204067_at SUOX .006189 3.84 Oxidoreductase activity
211162_x_at SCD .008776 3.78 Oxidoreductase activity
235851_s_at GNAS .008694 3.76 Melanogenesis
208664_s_at TTC3 .009661 3.71 Unknown
214462_at SOCS6 .005361 3.66 JAK-STAT cascade
204112_s_at HNMT .007766 3.65 Methyltransferase activity
231169_at TXLNA .030896 3.63 Unknown
222420_s_at UBE2H .004784 3.61 Ubiquitination
219915_s_at SLC16A10 .008258 3.60 Transporter activity
1564053_a_at YTHDF3 .00605 3.59 Unknown
221833_at LONP2 .001776 3.59 Unknown
230730_at SGCD .013282 3.57 Cytoskeleton organization
222294_s_at EIF2C2 .00315 3.56 MicroRNA processing
209727_at GM2A .008281 3.55 Glycolipid catabolic process
213543_at SGCD .003471 3.55 Unknown
209629_s_at NXT2 .007228 3.52 Unknown
201559_s_at CLIC4 .016006 3.51 Voltage-gated chloride channel activity
214449_s_at RHOQ .002114 3.51 GTP binding protein
239131_at ADNP .00798 3.50 Regulation of transcription
204271_s_at EDNRB .007963 3.50 Receptor activity (melanocyte differentiation)
202743_at PIK3R3 .022772 3.46 Phosphoinositide 3-kinase regulator activity
203300_x_at AP1S2 .001801 3.42 Protein binding
201048_x_at RAB6A .004873 3.38 GTPase activity
228315_at Unknown .014408 3.38 Unknown
201337_s_at VAMP3 .003625 3.36 Membrane fusion
211708_s_at SCD .003006 3.35 Oxidoreductase activity
206426_at MLANA .001163 3.35 Pigmentation
228188_at FOSL2 .013341 3.29 Transcription factor
238478_at BNC2 .00454 3.29 Regulation of transcription
204426_at TMED2 .006716 3.26 Protein binding
225949_at NRBP2 .00202 3.26 Unknown
212390_at PDE4DIP .039394 3.25 Unknown
223940_x_at MALAT1 .006315 3.25 Malignant phenotype
218175_at CCDC92 .045537 3.24 Unknown
211711_s_at PTEN .025667 3.22 Phosphatidylinositol-3,4,5-trisphosphate 3-phosphohydrolase activity
209034_at PNRC1 .001939 3.22 Protein binding
208490_x_at HIST1H2BF .004021 3.21 DNA Binding
201008_s_at TXNIP .00239 3.20 Protein binding/apoptosis
213872_at C6orf62 .04881 3.20 Unknown
209515_s_at RAB27A .008875 3.19 GTPase activity
205348_s_at DYNC1I1 .028465 3.17 Microtubule binding
233559_s_at WDFY1 .002014 3.16 Phosphatidylinositol binding
212806_at KIAA0367 .007275 3.16 Unknown
240555_at MITF .009133 3.16 DNA binding
239239_at Unknown .008556 3.15 Unknown
214544_s_at SNAP23 .034993 3.15 Regulator of transport
222555_s_at MRPL44 .005802 3.15 Unknown
229150_at MLPH .005347 3.14 Rab GTPase binding (melanogenesis)
218559_s_at MAFB .020548 3.14 Transcription factor
241966_at MYO5A .004563 3.11 Actin filament binding
225863_s_at C19orf12 .008061 3.11 Unknown
229942_at Unknown .002483 3.10 Unknown
1559776_at GM2A .018428 3.10 β-N -Acetylhexosaminidase activity
231337_at Unknown .00422 3.10 Unknown
206498_at OCA2 .010334 3.10 Transporter activity
242100_at CHSY2 .005872 3.09 Glycosyltransferase
206132_at MCC .007443 3.08 Negative regulation of cell cycle
211890_x_at CAPN3 .002934 3.07 Calpain activity
220494_s_at Unknown .003459 3.05 Unknown
227542_at SOCS6 .004468 3.04 Jak-STAT cascade
200878_at EPAS1 .012338 3.04 Transcription factor
216513_at DCT .006938 3.04 Dopachrome isomerase activity (melanogenesis)
236953_s_at Unknown .014355 3.02 Unknown
212347_x_at MXD4 .004786 3.02 Transcription repressor
215913_s_at GULP1 .01189 3.01 Apoptosis
204427_s_at TMED2 .004092 3.01 Protein binding
230722_at BNC2 .008834 3.00 Regulation of transcription
217523_at CD44 .005237 3.00 Integral to plasma membrane
221834_at LONP2 .004434 3.00 Proteolysis
208893_s_at DUSP6 .045994 −94.88 MAPK phosphatase activity
208891_at DUSP6 .026377 −73.44 MAPK phosphatase activity
Table W1. (continued )
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208892_s_at DUSP6 .006669 −28.88 MAPK phosphatase activity
220945_x_at MANSC1 .005651 −26.47 Unknown
204011_at SPRY2 .0166 −19.41 Negative regulation of MAP kinase activity
206256_at CPN1 .018433 −17.38 Carboxypeptidase A activity
221911_at Unknown .021372 −16.39 Unknown
206115_at EGR3 .004486 −15.52 Transcription regulator
211603_s_at ETV4 .000926 −14.34 Malignant phenotype/cell cycle progression
228442_at NFATC2 .020553 −14.13 Positive regulation of transcription (MAPK pathway)
204420_at FOSL1 .008339 −12.01 Transcription factor activity
225864_at FAM84B .001617 −10.96 Unknown
1554576_a_at ETV4 .002342 −10.66 Malignant phenotype/cell cycle progression
204973_at GJB1 .002342 −10.40 Cell-cell signaling
228170_at OLIG1 .016426 −10.15 DNA binding
226991_at NFATC2 .000947 −9.91 Positive regulation of transcription (MAPK pathway)
208712_at CCND1 .004185 −9.45 Cyclin-dependent protein kinase regulator activity
209498_at CEACAM1 .002482 −9.34 Angiogenesis (melanoma metastasis)
221577_x_at GDF15 .018219 −9.25 Growth factor activity
204401_at KCNN4 .004647 −8.89 Ion channel activity
204286_s_at PMAIP1 .028421 −8.76 Apoptosis
201631_s_at IER3 .004722 −8.54 Antiapoptosis
221489_s_at SPRY4 .002903 −8.49 Negative regulation of MAP kinase activity
206097_at SLC22A18AS .008533 −8.41 Unknown
204014_at DUSP4 .030346 −7.92 MAPK phosphatase activity
208711_s_at CCND1 .004636 −7.12 Cyclin-dependent protein kinase regulator activity
226034_at Unknown .011213 −6.97 Unknown
210233_at IL1RAP .027752 −6.90 Transmembrane receptor activity
204015_s_at DUSP4 .01126 −6.75 MAPK phosphatase activity
201581_at Unknown .021832 −6.22 Unknown
202458_at PRSS23 .009042 −6.21 Peptidase activity
216375_s_at Unknown .004383 −5.99 Unknown
205287_s_at TFAP2C .003881 −5.96 Transcription factor activity
202431_s_at MYC .042018 −5.91 Transcription factor activity
227445_at Unknown .043661 −5.85 Unknown
223633_s_at BCAN .01462 −5.70 GPI anchor binding
1566968_at SPRY4 .003695 −5.64 Negative regulation of MAP kinase activity
218113_at TMEM2 .025243 −5.58 Unknown
230121_at Unknown .019511 −5.57 Unknown
203348_s_at ETV5 .017637 −5.51 Transcription factor activity
222962_s_at MCM10 .004454 −5.46 DNA replication
204254_s_at VDR .01322 −5.30 Vitamin D3 receptor
227294_at Unknown .013752 −5.20 Unknown
201150_s_at TIMP3 .006581 −5.16 Metalloendopeptidase inhibitor activity
219710_at SH3TC2 .004587 −5.11 Unknown
201147_s_at TIMP3 .04306 −5.02 Metalloendopeptidase inhibitor activity
218574_s_at LMCD1 .01638 −4.97 Protein-protein interaction
226279_at PRSS23 .005477 −4.97 Peptidase activity
201580_s_at TXNDC13 .002725 −4.92 Electron transport
203349_s_at ETV5 .012014 −4.84 Transcription factor activity
203320_at SH2B3 .008023 −4.81 Intracellular binding cascade
204695_at CDC25A .022654 −4.80 Cell cycle
202644_s_at TNFAIP3 .047724 −4.76 Antiapoptosis
232674_at UCN2 .017306 −4.76 Hormone activity
202149_at NEDD9 .016723 −4.74 Protein binding
201645_at TNC .028016 −4.66 Unknown
218404_at SNX10 .008256 −4.64 Phosphoinositide binding
213113_s_at SLC43A3 .002349 −4.62 Unknown
205286_at TFAP2C .042416 −4.60 Transcription factor activity
201148_s_at TIMP3 .003436 −4.47 Metalloendopeptidase inhibitor activity
227812_at TNFRSF19 .033546 −4.47 Tumor necrosis factor activity (melanoma growth)
236044_at PPAPDC1A .004628 −4.44 Unknown
219959_at MOCOS .001491 −4.43 Molybdenum ion binding
205110_s_at FGF13 .018553 −4.34 Growth factor activity(MAPK)
240721_at BIN3 .002168 −4.32 Cytoskeletal adaptor activity
225685_at CDC42EP3 .005022 −4.30 Cytoskeletal regulatory protein binding protein
229674_at SERTAD4 .016623 −4.30 Unknown
204255_s_at VDR .005874 −4.18 Vitamin D3 receptor
208370_s_at RCAN1 .015409 −4.10 Transcription factor activity
225996_at Unknown .004868 −4.08 Unknown
230660_at SERTAD4 .021081 −4.02 Unknown
227188_at C21orf63 .001942 −3.99 Unknown
202643_s_at TNFAIP3 .003724 −3.97 Antiapoptosis
201596_x_at KRT18 .007871 −3.96 Cytoskeleton
216026_s_at POLE .004783 −3.91 DNA replication
238576_at Unknown .002944 −3.90 Unknown
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225167_at FRMD4A .004785 −3.89 Unknown
210692_s_at SLC43A3 .005345 −3.86 Unknown
225168_at FRMD4A .003096 −3.85 Unknown
203607_at INPP5F .018916 −3.82 Inositol phosphatase
205227_at IL1RAP .005039 −3.79 Transmembrane receptor activity
203967_at CDC6 .00274 −3.79 DNA replication
208916_at SLC1A5 .004127 −3.76 Transport
209832_s_at CDT1 .010927 −3.75 DNA replication
204967_at SHROOM2 .008573 −3.74 Actin filament binding
212501_at CEBPB .019184 −3.73 Transcription activator
201149_s_at TIMP3 .019481 −3.73 Metalloendopeptidase inhibitor activity
36711_at MAFF .017838 −3.72 Transcription factor activity
203438_at STC2 .00483 −3.68 Hormone activity
225777_at C9orf140 .002854 −3.60 Unknown
202664_at WIPF1 .011697 −3.60 Actin binding
209803_s_at PHLDA2 .01515 −3.58 Unknown
224480_s_at MAG1 .029302 −3.55 Transferase activity
201920_at SLC20A1 .003513 −3.53 Receptor activity
215498_s_at MAP2K3 .006256 −3.51 MAP kinase kinase activity
218368_s_at TNFRSF12A .040042 −3.51 Receptor activity
242931_at Unknown .029157 −3.48 Unknown
207604_s_at SLC4A7 .024391 −3.47 Receptor activity
204790_at SMAD7 .004846 −3.47 TGF inhibition
211143_x_at NR4A1 .010408 −3.45 Apoptosis (MAPK)
217388_s_at KYNU .005594 −3.44 Hydrolase activity
204470_at CXCL1 .021083 −3.44 Chemokine activity
242455_at POU3F2 .012401 −3.43 Transcription factor (melanoma and MAPK)
201012_at ANXA1 .016848 −3.42 Tumor suppressor (activator of p38 and JNK)
225007_at G3BP1 .034172 −3.41 RNA binding protein
225699_at C7orf40 .011676 −3.38 Unknown
218931_at RAB17 .00562 −3.34 GTP binding
214281_s_at RCHY1 .009293 −3.33 p53 degradation
219361_s_at ISG20L1 .034059 −3.32 Unknown
229551_x_at ZNF367 .005901 −3.30 Unknown
226722_at FAM20C .01556 −3.30 Unknown
230494_at Unknown .002275 −3.30 Unknown
201890_at RRM2 .033374 −3.29 DNA replication
224579_at SLC38A1 .001375 −3.29 Unknown
227093_at USP36 .032077 −3.29 Deubiquitination
204698_at ISG20 .042731 −3.27 Unknown
212730_at DMN .007783 −3.26 Filament
33304_at ISG20 .001808 −3.26 Unknown
202081_at IER2 .012051 −3.24 Unknown
210663_s_at KYNU .003893 −3.24 Hydrolase activity
202684_s_at RNMT .010045 −3.23 Methyltransferase activity
207735_at RNF125 .007599 −3.18 Unknown
231775_at TNFRSF10A .02477 −3.18 Apoptosis
221841_s_at KLF4 .018073 −3.18 Negative regulation of cell cycle
41037_at TEAD4 .020586 −3.16 Transcription factor
222199_s_at BIN3 .001159 −3.15 Cytoskeletal adaptor activity
242149_at Unknown .009927 −3.15 Unknown
225722_at Unknown .024201 −3.13 Unknown
212563_at BOP1 .004875 −3.11 RNA processing
218585_s_at Unknown .004016 −3.09 Unknown
203044_at CHSY1 .012693 −3.07 Transferase activity
204519_s_at PLLP .012214 −3.07 Unknown
209928_s_at MSC .026968 −3.07 Transcription corepressor
201656_at ITGA6 .008856 −3.06 Cell adhesion
219257_s_at SPHK1 .00561 −3.05 ATP-binding
203395_s_at HES1 .007811 −3.05 Transcription repressor activity
223414_s_at LYAR .001947 −3.03 Unknown
215156_at WDR61 .025595 −3.03 Unknown
209288_s_at CDC42EP3 .04212 −3.03 Cytoskeleton regulatory protein
205264_at CD3EAP .031768 −3.03 Polymerase activity
202613_at CTPS .014422 −3.02 CTP synthase activity
223700_at MND1 .003021 −3.02 Unknown
233803_s_at MYBBP1A .00169 −3.02 Transcription factor binding
209884_s_at SLC4A7 .036205 −3.00 Receptor activity
Probe sets are rank-ordered according to their fold change.
*Minus before fold change indicates genes downregulated in PD0325901-treated cells.
